Abstract
Fludarabine phosphate is currently proposed for the treatment of refractory chronic lymphocytic leukemia (CLL). CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy. We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate. The patient developed a severe infection of the upper and lower respiratory tract with bilateral pulmonary infiltrates and severe hypoxemia. RSV was the only infectious agent that could be isolated, and treatment with aerosolized ribavirin lead to prompt improvement of all symptoms.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 8 December 1997 / Accepted: 26 January 1998
Rights and permissions
About this article
Cite this article
Eftekhari, P., Lassoued, K., Oksenhendler, E. et al. Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia. Ann Hematol 76, 225–226 (1998). https://doi.org/10.1007/s002770050394
Issue Date:
DOI: https://doi.org/10.1007/s002770050394